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 and S. M. Turega
a 
Double mutant cycles were constructed using neurotransmitters 
and synthetic substrates that measure their selective binding to 
one monoamine oxidase (MAO) enzyme isoform over another as a 
function of structural change. This work measures a reduction in 
selectivity for the MAOB isoform of 3 to 9.5 kJ/mol on the 
addition of hydroxy functional groups to a phenethylamine 
scaffold. Replacement of hydroxy functional groups on the 
phenethylamine scaffold by hydrophobic substituents measures 
an increase in selectivity for MAOB of -1.1 to -6.9 kJ/mol. The 
strategies presented here can be applied to the development of 
competitive reversible inhibitors of MAO enzymes and other 
targets with structurally related isoforms. 
Introduction 
Neurotransmitters containing a phenethylamine scaffold are 
integral to signalling process in the central nervous system. These 
amines can be oxidised, decommissioning them by the monoamine 
oxidase (MAO) enzymes. The inhibition of these enzymes is a target 
for therapeutic development with the selectivity of candidate 
molecules for one isoform over another being a key consideration. 
Current drug development programs target the MAO enzymes 
along with transport proteins and receptors that bind the 
neurotransmitters decommissioned by the MAO enzymes.
1
 The 
understanding of substrate and inhibitor binding is required for the 
development of effective inhibitors of these targets for the 
treatment of central nervous system (CNS) disorders, with focus on 
competitive inhibitors selective for monoamine oxidase B (MAOB) 
over monoamine oxidase A (MAOA). The understanding of 
selectivity of small molecule binding to the MAO enzymes and other 
neurotransmitter binding targets can be considered an important 
goal in the development of new selective inhibitors.
2-5
 The target 
binding for both irreversible and reversible competitive inhibitors is 
the enzyme’s active site where the redox cofactor flavin adenine 
dinucleotide (FAD) is located. MAOA and MAOB are mainly localized 




Figure 1. Theoretical dissection of dopamine, 1 to give phenethylamine, 2 via 3 or 4 
through the stepwise substitution of individual functional groups. 
In humans the MAO isoforms MAOA and MAOB share a 73% 
sequence homology, the selectivity of the MAO isoforms for 
endogenous neurotransmitters is provided by the size, shape and 
amino acid functionality of the enzymes active sites. Specifically the 
active site of MAOA has a volume of ≈550 Å
3
 that of MAOB ≈700 Å
3
, 
there are nine residues that differ between the isoforms and six 
residues where α-carbon positions vary more than 0.5 Å between 
the isoforms.
8
 A logical step the in development of more selective 
inhibitors is to build a quantitative understanding of substrate 
recognition describing what structural changes provide the 
observed isoform selectivity. The molecular recognition of host-
guest binding events can be quantified and rationalised at the level 
of individual interactions using double mutant cycles (DMCs). This 
strategy has been used to study the protein folding through DMCs, 
synthetic host guest interaction with chemical DMCs, the effect of 
conformational restriction of binding affinities and the molecular 
recognition of supramolecular cage-guest systems.
9-15
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functional groups around a neurotransmitter substrate or inhibitor 
scaffold result in contributions from the resulting non-covalent 




Results and discussion 
This work reports mixed double mutant cycles which, through 
structural changes in enzyme MAOB to MAOA and structural 
changes in substrate, substitution of functional groups around the 
ring of a phenethylamine scaffold produce DMCs that dissect the 
differing molecular recognition afforded by the MAO isoforms 
active sites. Parallels can be drawn between the reversible binding 
of a neurotransmitter substrate and the binding of a competitive 
inhibitor to an MAO isoform’s active site (Figure S1). The 
understanding of how changes in substrate structure affect isoform 
selectivity can be transposed onto the design and subsequent 
improvement in selectivity of small molecule inhibitors for these 
targets. 
Table 1. Michaelis-Menten parameters for compounds 1-7 measured 310 K with both 
MAOA and MAOB. 
 MAOA  MAOB  
Substrate Ks / μM kcat / min
-1 Ks / μM kcat / min
-1 
1 260 ±10 0.40 ±0.12 400 ±100 0.11 ± 0.036 
 
2 1600 ±50 0.29 ±0.02 1600 ±80 0.066 
±0.006 
3 2300 ±6 5.6 ±1.2 54 ±4 0.048 ±0.04 
4 490 ±20 0.84 ±0.12 230 ±50 0.72 ±0.12 
5 45 ±3 0.54 ±0.12 29 ±2 10 ±1 
6 300 ±20 0.78 ±0.18 15 ±3 14 ±6 
7 69 ±4 2.3 ±0.6 7.7 ±2 33 ±1 
 
To understand the selectivity of these neurotransmitters for one 
isoform over another the dissection of dopamine 1 was visualised 
one substitution at a time to give its phenethylamine 3 
neurotransmitter core, through the tyramine 2 substrate and 3-(2-
aminoethyl)phenol 4 shown in figure 1. This involves replacing the 
para and meta hydrogens of the phenyl ring in phenylethylamine 3 
with a hydroxy functional group to give the di-substituted ring of 2 
or 4 after a single substitution; a further substitution to add a 
second hydroxy group gives the target dopamine, 1. In the step 
wise substitution of phenylethylamine 3 to give dopamine 1 the size 
and polarity of the substrate is increased specifically by two hydroxy 
functional groups comprising of an oxygen hydrogen bond acceptor 
and a hydrogen bond donor. Dopamine 1 is a key neurotransmitter 
in the CNS, tyramine 2 promotes the release of monoamine release 
from presynaptic neurons, phenethylamine 3 acts as a stimulant or 
neuromodulator in the CNS of humans.
17
  
The ethylamine functionality in these neurotransmitters is 
catalytically oxidised by the MAO to the corresponding 
acetaldehyde producing a stoichiometric equivalent of hydrogen 
peroxide that can be observed in real time producing kinetic data 
with an Amplex Red™ enzyme coupled fluorescent assay. For 
substrates that show a good fit to Michaelis–Menten enzyme 
kinetics the substrate binding constant (Ks) measures the substrate 
affinity for the MAO active site, equation (1). Michaelis-Menten 
data sets were collected for substrates 1 to 7 with both MAOA and 
MAOB to allow the construction of DMCs (figure 2) through the 
variation of substituents R1 and R2 to dissect the substrate 
molecular recognition shown in figure 1. The concentration of 
hydrogen peroxide formation in the reactions was converted to 
molar values using an Amplex Red™ standard curve and plotted as a 
function of time, the linear portions of these reaction profiles were 
fit to a straight line to give a v0 value. The Michaelis Menten curves 
produced from these data sets were fitted to equation (1) using 
nonlinear regression to give Ks and kcat parameters, Table 1. The Ks 
values range from 45-2300 μM for MAOA and 7.7-1600 μM for 
MAOB, these values are used in DMC calculations, kcat values are 
within the range expected. Recent approvals of 
"Xadago"(safinamide) a competitive (non-covalent) reversible 
MAOB inhibitor and much development of trend small molecule 
inhibitors for MAOB focuses on competitive (non-covalent) 
reversible MAO inhibitors. In this work to further develop that 
direction, the analysis developed focuses on the molecular 
recognition of the reversible substrate binding step (Figure S1), the 
Ks and corresponding free energy of substrate binding (ΔGs) binding 
terms (Table S1).  
v = [E]0[S]kcat / Ks + [S]  (1) 
 
DMC method: phenylethylamine 3 to tyramine 2. The first DMC 
needed to investigate the structural changes in figure 1 is the 
substitution of the para-hydrogen in phenylethylamine 3 by a para-
hydroxy to give tyramine 2, using equation (2). The step wise DMC 
in figure 3 shows the free energy change (ΔΔG) for each single 
mutation that makes up the whole cycle. For each mutation of the 
cycle a single mutant ΔΔG is calculated by subtracting the ΔG for 
the product complex from the ΔG of the starting complex, following 
the direction of the arrows in figure 3. The single mutant MAOB•R2 
to MAOA•R2 changing the enzyme MAOB to MAOA with the same 
substrate gives the difference in substrate binding of tyramine 2 
between MAOB and MAOA as a negligible change -0.1 kJ/mol, the 
single mutant MAOB•R1 to MAOA•R1 difference between 
substrate binding of phenylethylamine 3 between the MAOB and 
MAOA is a favourable -9.5 kJ/mol. When the single mutant 
MAOB•R2 to MAOB•R1 changes the substrate for the same 
enzyme adding a para-hydroxy to phenylethylamine 3 to give 
tyramine 2 with MAOB this gives an unfavourable change in 
substrate binding of 8.6 kJ/mol the same single mutant MAOA•R2 
to MAOA•R1 change with MAOA gives a small favourable change in 
binding of -0.9 kJ/mol. Subtracting the ΔΔG values for parallel 
mutations of the DMC (equqtion (2)) gives the change in selectivity 
for MAOB as a function of functional group substitution, meaning 
the addition to the phenylethylamine 3 scaffold of a para-hydroxy 
makes the tyramine 2 substrate bind 9.5 ±0.6 kJ/mol with lower 
affinity to MAOB relative to MAOA.  
ΔΔG = ΔGMAOA•R1 - ΔGMAOB•R2 - ΔGMAOA•R1 + ΔGMAOB•R2  (2) 
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Figure 2. Theoretical dissection of dopamine, 1 to give phenethylamine, 2 via 3 or 4 
through the stepwise substitution of individual functional groups. 
 
Table 2. Measured ΔΔG for the DMC in fig. 3 that dissect the molecular recognition of 
dopamine 1 in a series of stepwise substitutions, measured at 310K. 
 R1  R2 ΔΔG / 
kJ/mol 
1 m-OH, p-OH 7 m-Me, p-Me -6.9 ± 0.9 
2 m-H, p-OH 1 m-OH, p-OH 1.2 ± 0.7 
2 m-H, p-OH 5 m-H, p-Me -1.1 ± 0.2 
3 m-H, p-H 2 m-H, p-OH 9.5 ± 0.6 
3 m-H, p-H 4 m-OH, p-H 7.7 ± 0.8 
4 m-OH, p-H 1 m-OH, p-OH 3.0 ± 0.9 
4 m-OH, p-H 6 m-OMe, p-H -5.7 ± 0.6 
5 m-H, p-Me 7 m-OH, p-OH -4.5 ± 0.6 
 
Stepwise dissection of dopamine by DMC: phenylethylamine 3 to 
dopamine 1. The seven substrates, three endogenous and four 
synthetic are required for the functional group substitutions that 
describe the dissection of dopamine 1 to give phenylethylamine 3 
using the eight DMCs shown in figure 4(a). The ΔΔG values for the 
DMC required are calculated using equation (2) and presented in 
Table 2. To investigate the addition of hydroxy groups to the 
phenylethylamine 3 scaffold four DMCs are constructed 3 to 2, 3 to 
4, 2 to 1 and 4 to 1. The DMCs describing the substitution of para or 
meta positions on the phenylethylamine 3 scaffold for hydroxy 
groups to give tyramine 2 or 3-(2-aminoethyl)phenol 4 give a 
reduction in selectivity for MAOB of 9.5 and 7.7 kJ/mol respectively. 
The DMCs describing the substitution of the remaining meta or 
para substituent on tyramine 2 or 3-(2-aminoethyl)phenol 4 for a 
second hydroxy group to give dopamine 1 gives a further small 
reduction in selectivity for MAOB of 1.2 and 3.0 kJ/mol. This shows 
a progressive decrease in selectivity for MAOB as two hydrogens 
around the aromatic ring are replaced with larger and more polar 
hydroxy functional groups. To investigate the role of the hydrogen 
bond donors in tyramine 2, 3-(2-aminoethyl)phenol 4 and 
dopamine 1 analogues that no longer have the hydrogen bond 
donor of the hydroxy substituent; 2-(p-tolyl)ethan-1-amine 5, 2-(3-
methoxyphenyl)ethan-1-amine 6 and 2-(3,4-dimethylphenyl)ethan-
1-amine 7 were used to build the three three DMCs 2 to 5, 4 to 6 
and 1 to 7 in Figure 2. The DMCs built from substituting the para-
hydroxy of tyramine 2 for a para-methyl to give 2-(p-tolyl)ethan-1-
amine 5 makes the substrate -1.1 kJ/mol slightly more selective for 
MAOB. An overview of the data in figure 4(a) is presented as a 
column graph in figure 4(b) to aid the visualisation of continuum of 
data presented.  
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Figure 3. DMC method: phenylethylamine 3 to tyramine 2. A mixed double mutant cycle describing the addition of a p-OH to phenylethylamine 3 to give tyramine 2, built by the 
substitution of R2 for R1 where R1 the p-H in 3 is substituted with R2 the p-OH in 2. with MAOA and MAOB which describing change in selectivity of binding to MOAB for this 
substitution. Active site residues that differ between the MAOA and MAOB are shown in black, residue positions that move more than 0.5 Å are shown in purple, residues that 
both differ and move more than 0.5 Å are shown in orange. 
 
The DMCs substituting the meta-hydroxy of 3-(2-aminoethyl)phenol 
4 for meta-methoxy in 2-(3-methoxyphenyl)ethan-1-amine 6 makes 
the substrate -5.7 kJ/mol more selective for MAOB; substituting the 
para-hydroxy and the meta-hydroxy of dopamine 1 for para-methyl 
and meta-methyl to give 2-(3,4-dimethylphenyl)ethan-1-amine 7 
results in this substrate being -6.9 kJ/mol more selective for MAOB. 
Relating these results to the structure of the MAO active sites, an 
increase in hydrophobic surface area groups provides an increase in 
MAOB selectivity and a decrease in hydrophobic functional groups 
provides a decrease in selectivity for MAOB. An explanation for this 
observation is the increased size of the MAOB cavity compared to 
that of MAOA provides a decreased opportunity for favourable 
hydrophobic contacts between the substrate active site 
The bulk treatment of substitutions changing hydrogen bond 
donors, hydrogen bond acceptors and hydrophobic contacts 
neglects the powerful selectivity of enzyme active sites. To probe 
this important aspect of substrate recognition the ΔΔG of substrate 
binding for the substitution of phenethylamine 3 for the individual 
enzymes, MAOA and MAOB is shown in Tables S2 and S3. For 
MAOA all substitutions of phenethylamine 3 result in an increase in 
substrate binding affinity but for MAOB only substitutions that lack 
a hydrogen donor result in an increase in substrate binding affinity, 
substitutions that involve the addition of a hydrogen bond acceptor 
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Figure 4. (a) Stepwise dissection of dopamine by DMC: phenylethylamine 3 to dopamine 1. Values of ΔΔG at 310 K for DMCs that describe the change in selectivity for MAOB over 
MAOA for the substitution of the p-H and m-H of phenethylamine 3 for hydroxy groups to give substrates 1,2, and 4; using the ΔΔG values for 3 to 2, 2 to 5, 4 to 1 and 2 to 1. For 
the loss of hydrogen bond donors values of ΔΔG at 310 K for DMCs that describe the change in selectivity for MAOB over MAOA for loss of hydroxy groups  to give substrates 5, 6 
and 7; using the ΔΔG values for 2 to 5, 5 to 7, 1 to 7 and 4 to 6. (b) Data from Stepwise dissection of dopamine by DMC: phenylethylamine 3 to dopamine 1 represented as a 
column graph. 
 
Structural data for competitive (non-covalent) reversible inhibitors 
bound to MAOA and MAOB as host-guest complexes was retrieved 
from the protein data bank, the reversible inhibitors bind to the 
MAO active site through hydrogen bonds to the FAD cofactor, ring 
to carbonyl π-stacking, hydrophobic contacts, hydrogen bond from 
active site residues to the bound inhibitor and hydrogen bonds 
from the bound inhibitor to ordered active site waters.
18-20
 
Increasing the hydrophobic surface area of substrates can increase 
the opportunity for hydrophobic contacts and the displacement of 
cavity waters increasing the magnitude of the hydrophobic 
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21-23
 Addition of specific hydrogen bonds 
between inhibitors and enzyme active sites confers stability to the 
enzyme substrate complex; here we demonstrate that the addition 
of hydrogen bond donors reduces the strength of substrate binding 
to MAOB. Substitution of a hydrogen bond donor containing 
functionality for one without the hydrogen bond donor makes a 
substrate more selective for MAOB. To rationalise these 
observations we use the GOLD docking software to generate 
binding poses of the substrates to the active sites of the MAOA and 
MAOB enzymes. This was achieved using crystal structures of 
MAOA (PDB code: 2Z5X) and MAOB (PDB code: 3PO7) containing 
small competitive (non-covalent) reversible inhibitors in the active 
site. The docking studies produced favourable binding 
conformations for MAOB with substrates 1, 2 and 4 that contained 
a hydrogen bond between the amide carbonyl of Ile-199 and a 
substrate hydroxy group. In MAOA the Ile-199 residue is mutated to 
Phe208 again favourable binding conformations hydrogen bonds 
between the hydroxy groups of 1, 2 and 4 and the Phe208 residue 
were observed Figure 2 and Figure S1. As both active sites have the 
capacity to form similar hydrogen bonds to the substrates it is 
possible to consider that the behaviours observed are due to a 
reduction in hydrophobic surface area upon a substitution of a 
hydrogen atom for a polar hydroxy group and the effect this has on 
hydrophobic contacts between a larger MAOB and smaller MAOA 
active site cavity.  
 
Figure 5, The plot of change in molecular volume (ΔMV / Å
3
) against ΔΔG for the DMC 
in built from all possible combinations of single and double functional group 
substitutions using substrates 1 to 7, the linear trend line has R
2
 = 0.763. 
To further understand the balance between polar hydrogen bond 
donors and hydrophobic substituents a further nine DMC were built 
from all possible combinations of single and double functional 
group substitutions using substrates 2 to 7 to investigate the 
substitution of polar substituents for none polar substituents. The 
G for these 15 cycles that describe the substitution of polar 
substituents for non-polar substituents can be plotted against the 
structural parameters, change in; molecular volume, surface area 
and total polar surface area (TPSA) figures 5, S3 and S4 respectively. 
The plot that demonstrate the best correlation is figures 5, change 
in molecular volume, can be related to exclusion of waters and 
increased hydrophobic contacts, there is a l trend for an increase in 
MAOB selectivity as molecular volume increases. The larger the 
change in; molecular volume or surface area the larger the increase 
selectivity for MAOB, making this a useful structural parameter for 
use in considering the selection of functional groups for substitution 
in and addition to an inhibitor scaffold. Variance in these plots is 
likely due to mismatches between the structures of the substrates 
and the enzyme active site, this can be explored as the number of 
examples is increased in future work. There is a less strong 
correlation between surface area or TPSA and selectivity for 
MAOB figure S3 and S4. 
Conclusion 
The DMC constructed in this work describe the specific 
substitutions of single and double function groups around a 
phenethylamine scaffold, DMC have been constructed in order to 
calculate the change in selectivity of substrate binding for MAOB 
over MAOA as a result of these substitutions. Seven substrates have 
been used to dissect the molecular recognition of the key 
neurotransmitter dopamine 1; these include both endogenous and 
synthetic substrates for the MAO enzymes. These cycles have been 
used to build up a molecular recognition profile for dopamine 1 
probing the free energy-structure profiles for increasing substrate 
surface area and number of hydrogen bond donors. This suggests a 
relationship between the amount of hydrophobic contacts in the 
substrate-enzyme complex and free energy of substrate binding as 
demonstrated previously by synthetic ligand-receptor studies in 
water.
24
 The DMC approach and data presented here can be 
applied to achieve this structural changes have to occur that result 
in a molecular recognition interface that is made up of multiple 
weak interactions. Through the inclusion of additional weak 
interactions and the optimisation of the efficiency with which each 
of the weak interactions is made the affinity of the inhibitor for the 
active site can be increased.
25, 26
 The effect of adding functional 
groups that form additional weak interactions and structural 
changes to functional group that already make interactions can be 
quantified using this DMC approach. Initial results suggest that 
addition of bulky and hydrophobic substituents can be used to 
make inhibitors more selective for MAOB the effect of this on a 
substituted inhibitor scaffold can be quantified through the 
construction of further DMCs. The data collected will expand data 
sets that allow the determination of general trends and correlations 
that can influence further development. To utilise the data sets 
collected and address selectivity in a predictive way the data points 
collected can be used to build a training set for a linked theoretical 
approach using a bespoke scoring function for docking software this 
approach can be used as a powerful predictive tool for the virtual 
screening of large compound libraries containing accessible 
functional group substitutions for the effect on isoform selectivity.
27
 
Considering that many biological macromolecules (in addition to 
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current drug targets this physical-organic chemistry approach can 
be transferred to further targets with structurally related isoforms, 
relevant to medicinal chemistry and elucidation of biological 
mechanisms.
28
 This will provide an understanding of the effects of 
structural changes on isoform selectivity allowing the development 
of more selective molecules. 
Experimental 
a full description of experimental work is included in the supporting 
information. 
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